Non-Interventional Prospective Observational Study of Platelet Rich Fibrin As a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Feb 15

PMID 35160132

Authors

Sebastian Blatt

Maximilian Kruger

Peer W Kammerer

Daniel G E Thiem

Philipp Matheis

Anne-Katrin Eisenbeiss

Jorg Wiltfang

Bilal Al-Nawas

Hendrik Naujokat

Affiliations

Soon will be listed here.

Abstract

Background: Medication-related osteonecrosis (MRONJ) of the jaw is a severe and feared side effect of antiresorptive therapy in the oncological setting. With growing evidence that impaired angiogenesis may represent a key factor in pathogenesis, the aim of this study was to evaluate an autologous platelet concentrate as a possible additive in surgical therapy to optimize vascularization and, subsequently, resolution rates.

Material And Methods: A non-interventional, prospective, multicenter study was conducted, and all patients with stage I-III MRONJ, undergoing antiresorptive therapy for an oncological indication, were included. The necrosis was treated surgically without (study arm A) or with (arm B) the addition of an autologous platelet concentrate (platelet-rich fibrin, PRF).

Results: After 5, 14, and 42 days postoperative, wound healing (primary outcome: mucosal integrity) as well as downstaging, pain perception, and oral health-related quality of life (secondary outcome) were assessed via clinical evaluation. Among the 52 patients included, primarily with MRONJ stage I and II, the use of PRF as an additive in surgical therapy did not display a significant advantage for wound healing ( = 0.302), downstaging ( = 0.9), pain reduction ( = 0.169), or quality of life ( = 0.9).

Summary: In conclusion, PRF as an adjunct did not significantly optimize wound healing. Further, no significant changes in terms of downstaging, pain sensation, and oral health-related quality of life were found.

Citing Articles

Using platelet concentrates to treat maxillofacial tissue lesions.

Liu R, Chen S, Wang P, Bi R Front Bioeng Biotechnol. 2025; 12():1523225.

PMID: 39845369 PMC: 11752918. DOI: 10.3389/fbioe.2024.1523225.

Use of platelet concentrates in oral surgery of patients with osteonecrosis: a scoping review.

Rufato C, Prado M, Luft R, Zauza D, Silva-Sousa Y, Santos M Braz Dent J. 2023; 34(2):1-13.

PMID: 37194847 PMC: 10208296. DOI: 10.1590/0103-6440202305254.

Evaluation of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Terms of Staging and Treatment Strategies by Dental Students at Different Educational Levels.

Heimes D, Mark N, Kuchen R, Pabst A, Becker P, Kyyak S Medicina (Kaunas). 2023; 59(2).

PMID: 36837455 PMC: 9962432. DOI: 10.3390/medicina59020252.

Reporting Criteria for Clinical Trials on Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review and Recommendations.

Gaudet C, Odet S, Meyer C, Chatelain B, Weber E, Parmentier A Cells. 2022; 11(24).

PMID: 36552861 PMC: 9777472. DOI: 10.3390/cells11244097.

References

Giudice A, Antonelli A, Chiarella E, Baudi F, Barni T, Di Vito A . The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes. Pharmaceuticals (Basel). 2020; 13(12). PMC: 7760182. DOI: 10.3390/ph13120423. View

Govaerts D, Piccart F, Ockerman A, Coropciuc R, Politis C, Jacobs R . Adjuvant therapies for MRONJ: A systematic review. Bone. 2020; 141:115676. DOI: 10.1016/j.bone.2020.115676. View

Fortunato L, Bennardo F, Buffone C, Giudice A . Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. J Craniomaxillofac Surg. 2020; 48(3):268-285. DOI: 10.1016/j.jcms.2020.01.014. View

Beth-Tasdogan N, Mayer B, Hussein H, Zolk O . Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017; 10:CD012432. PMC: 6485859. DOI: 10.1002/14651858.CD012432.pub2. View

Miron R, Zucchelli G, Pikos M, Salama M, Lee S, Guillemette V . Use of platelet-rich fibrin in regenerative dentistry: a systematic review. Clin Oral Investig. 2017; 21(6):1913-1927. DOI: 10.1007/s00784-017-2133-z. View

Gao S, Zheng G, Wang L, Liang Y, Zhang S, Lao X . Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB. PLoS One. 2017; 12(6):e0179248. PMC: 5464661. DOI: 10.1371/journal.pone.0179248. View

Di Vito A, Chiarella E, Baudi F, Scardamaglia P, Antonelli A, Giudice D . Dose-Dependent Effects of Zoledronic Acid on Human Periodontal Ligament Stem Cells: An Pilot Study. Cell Transplant. 2020; 29:963689720948497. PMC: 7784504. DOI: 10.1177/0963689720948497. View

Klingelhoffer C, Zeman F, Meier J, Reichert T, Ettl T . Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws. J Craniomaxillofac Surg. 2016; 44(10):1694-1699. DOI: 10.1016/j.jcms.2016.08.001. View

Kim J, Kim S, Kim M . Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg. 2014; 52(9):854-9. DOI: 10.1016/j.bjoms.2014.07.256. View

10.

Fortunato L, Barone S, Bennardo F, Giudice A . Management of Facial Pyoderma Gangrenosum Using Platelet-Rich Fibrin: A Technical Report. J Oral Maxillofac Surg. 2018; 76(7):1460-1463. DOI: 10.1016/j.joms.2018.01.012. View

11.

Carlson E, Basile J . The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl):85-95. DOI: 10.1016/j.joms.2009.01.006. View

12.

Zhang W, Gao L, Ren W, Li S, Zheng J, Li S . The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw. Front Immunol. 2021; 12:606043. PMC: 7947359. DOI: 10.3389/fimmu.2021.606043. View

13.

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

14.

Blatt S, Thiem D, Pabst A, Al-Nawas B, Kammerer P . Does Platelet-Rich Fibrin Enhance the Early Angiogenetic Potential of Different Bone Substitute Materials? An In Vitro and In Vivo Analysis. Biomedicines. 2021; 9(1). PMC: 7827266. DOI: 10.3390/biomedicines9010061. View

15.

Hamzani Y, Chaushu G . Evaluation of early wound healing scales/indexes in oral surgery: A literature review. Clin Implant Dent Relat Res. 2018; 20(6):1030-1035. DOI: 10.1111/cid.12680. View

16.

Capocci M, Romeo U, Guerra F, Mannocci A, Tenore G, Annibali S . Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study. Clin Ter. 2017; 168(4):e253-e257. DOI: 10.7417/T.2017.2015. View

17.

Thompson N, Gordey L, Bowles H, Parslow N, Houghton P . Reliability and validity of the revised photographic wound assessment tool on digital images taken of various types of chronic wounds. Adv Skin Wound Care. 2013; 26(8):360-73. DOI: 10.1097/01.ASW.0000431329.50869.6f. View

18.

de Cassia Tornier S, Macedo F, Sassi L, Schussel J . Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw. Support Care Cancer. 2021; 29(11):6713-6719. DOI: 10.1007/s00520-021-06275-w. View

19.

Fortunato L, Amato M, Simeone M, Bennardo F, Barone S, Giudice A . Numb chin syndrome: A reflection of malignancy or a harbinger of MRONJ? A multicenter experience. J Stomatol Oral Maxillofac Surg. 2018; 119(5):389-394. DOI: 10.1016/j.jormas.2018.04.006. View

20.

Yoshiga D, Nakamichi I, Yamashita Y, Yamamoto N, Yamauchi K, Nogami S . Prognosis factors in the treatment of bisphosphonate-related osteonecrosis of the jaw - Prognostic factors in the treatment of BRONJ. J Clin Exp Dent. 2014; 6(1):e22-8. PMC: 3935901. DOI: 10.4317/jced.51213. View